Anteris Technologies Secures $290 Million Financing Package Backed by Medtronic

2026-01-21 companies

Minneapolis, Wednesday, 21 January 2026.
Medtronic’s $90 million strategic investment anchors Anteris Technologies’ $290 million capital raise, providing critical validation and funding for the pivotal DurAVR heart valve trial.

Dual-Pronged Capital Injection

In a decisive move to fortify its balance sheet, Anteris Technologies Global Corp. (NASDAQ: AVR) announced the pricing of a substantial public offering on January 20, 2026 [1]. The structural heart company priced 34,782,609 shares of common stock at $5.75 per share, positioning the transaction to generate approximately $200 million in gross proceeds [1][5]. This public raise is bolstered by a concurrent strategic vote of confidence from Medtronic plc, which has agreed to purchase up to $90 million of common stock in a private placement [1][3]. The combined financing packages represent a potential influx of nearly $290 million to support the company’s clinical ambitions [7].

Strategic Alignment with Medtronic

The involvement of Medtronic offers significant industry validation for Anteris. Under the terms of the private placement, Medtronic will acquire a stake ranging between 16.0% and 19.99% of Anteris’ outstanding shares following the offering [2][4]. This investment is priced at the same $5.75 per share as the public offering and is contingent upon the successful completion of the public float [3][5]. The collaboration signals a deepening interest from the medical device giant in Anteris’ biomimetic valve technology, specifically as the company advances its lead product through critical regulatory phases [4].

Market Reaction and Valuation Impact

Investors reacted positively to the financing news and the strategic partnership, driving a sharp increase in market valuation. Following the announcement, Anteris stock surged 51.30% to trade at $8.70, significantly outpacing the offering price of $5.75 [5]. This rally added approximately $80 million to the company’s valuation, pushing its market capitalization to roughly $237 million [5]. Trading volume also spiked, reaching levels 25.1 times higher than the average, reflecting intense market interest in the capitalized path forward for the company [5].

Accelerating the DurAVR™ Clinical Strategy

The capital raised is explicitly earmarked to advance the clinical development of the DurAVR™ Transcatheter Heart Valve (THV). Anteris intends to use the net proceeds to fund the global pivotal PARADIGM Trial, which began enrolling patients in Denmark in late 2025 [1][5]. Beyond the trial, funds will support manufacturing expansion and continued research and development for v2vmedtech, inc. [1][2]. The public offering is expected to close on January 22, 2026, subject to customary closing conditions [1]. Additionally, underwriters have been granted a 30-day option to purchase up to 5,217,391 additional shares, which could add approximately 30.000 million dollars to the total gross proceeds if fully exercised [1].

Sources

Public Offering Medical Technology